MS & Immune Disorders
News
Promising Results Published for Pembrolizumab to Treat Progressive Multifocal Leukoencephalopathy
Tuesday, April 16, 2019—As published in the New England Journal of Medicine, positive results have been seen in a small study of pembrolizumab (Keytruda; Merck, Kenilworth, NJ) for treatment of …
FDA Approves Cladribine Tablets—First and Only Short-Course Treatment for Relapsing-Remitting MS
Monday, April 01, 2019—The Food and Drug Administration (FDA) has approved cladribine tablets (Mavenclad; EMD Serono, Rockland, MA) for treatment of relapsing-remitting multiple sclerosis (RRMS) and…
Siponimod Approved by FDA for Treatment of Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis
Wednesday, March 27, 2019—The first drug to treat 3 phases of multiple sclerosis (MS), secondary-progressive MS (SPMS), relapsing-remitting MS (RRMS), and clinically isolated syndrome (CIS), has b…
The Importance of Sleep
Logan Schneider, MD
March/April 2019—Sleep has a critical role in brain health and is an essential part of improving neurologic care for all of our patients.
Multiple Sclerosis Minute: Telemedicine and Multiple Sclerosis
Riley Bove, MD, MMSc; and Valerie J. Block, DPTSc, PT
March/April 2019—Telemedicine is acceptable to patients and clinicians in the continuum of clinic-to-in-home care and reduces barriers to care.
Dizziness and Vertigo
Ari A. Shemesh, MD; and Daniel R. Gold, DO
March/April 2019—Part 1: Untangling the complexity of dizziness and vertigo requires a careful history.
Patient’s Risk Tolerance for Disease Modifying Treatments for Multiple Sclerosis
Friday, March 15, 2019—In a study published in Neurology, researchers at the Cleveland Clinic evaluated patients’ tolerance for potential risks of multiple sclerosis (MS) medications. Stu…
Analysis of Cladribine Tablets Clinical Trials Continues to Support Safety and Efficacy
Thursday, March 07, 2019—In the 2-year CLARITY trial (NCT00213135), 47% of patients treated with cladribine tablets (CT) (EMD Serono; Rockland, MA) achieved no evidence of disease activity (NEDA) comp…
